Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later treatment

A. K. Conlin, B. M. Chun, V. F. Borges, N. M. Moxon, H. J. Parris, L. N. Walker, R. K. Murthy

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Cutaneous responses in HER2+ metastatic breast cancer: A retrospective case series of a Phase 1b study of Tucatinib, an Oral HER2-specific inhibitor in combination with Capecitabine and/or Trastuzumab in third-line or later treatment'. Together they form a unique fingerprint.

Medicine & Life Sciences